Advertisement
U.S. markets open in 9 hours 12 minutes
  • S&P Futures

    5,207.75
    -7.00 (-0.13%)
     
  • Dow Futures

    39,212.00
    -11.00 (-0.03%)
     
  • Nasdaq Futures

    18,179.50
    -52.00 (-0.29%)
     
  • Russell 2000 Futures

    2,047.50
    -2.30 (-0.11%)
     
  • Crude Oil

    82.52
    -0.20 (-0.24%)
     
  • Gold

    2,164.90
    +0.60 (+0.03%)
     
  • Silver

    25.33
    +0.07 (+0.28%)
     
  • EUR/USD

    1.0879
    +0.0002 (+0.02%)
     
  • 10-Yr Bond

    4.3400
    +0.0360 (+0.84%)
     
  • Vix

    14.33
    -0.08 (-0.56%)
     
  • GBP/USD

    1.2725
    -0.0004 (-0.03%)
     
  • USD/JPY

    149.7670
    +0.6690 (+0.45%)
     
  • Bitcoin USD

    65,586.58
    -2,089.30 (-3.09%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,722.55
    -4.87 (-0.06%)
     
  • Nikkei 225

    39,675.65
    -64.75 (-0.16%)
     

Actavis represents good takeover alternative for Pfizer, says Leerink

Leerink believes Actavis (ACT), post its buyout of Forest Labs, represents a good takeover alternative to AstraZeneca (AZN) for Pfizer (PFE). The firm says Actavis is one of the few pharma companies that meets the financial criteria necessary for Pfizer to accomplish a tax inversion. Leerink believes such a combination would be compelling.

Advertisement